Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Average Target Price of $26.25 According to Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $26.25.

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th.

Protara Therapeutics Stock Down 2.4%

Shares of TARA opened at $2.44 on Friday. Protara Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.82. The business has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $4.09.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). As a group, analysts expect that Protara Therapeutics will post -1.40 EPS for the current fiscal year.

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors have recently modified their holdings of the company. Corient Private Wealth LP purchased a new position in shares of Protara Therapeutics in the second quarter worth about $41,000. The Manufacturers Life Insurance Company raised its position in shares of Protara Therapeutics by 22.2% in the first quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock valued at $71,000 after purchasing an additional 2,464 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics in the second quarter valued at approximately $69,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Protara Therapeutics during the 2nd quarter valued at approximately $113,000. Finally, WINTON GROUP Ltd lifted its stake in shares of Protara Therapeutics by 16.7% during the 2nd quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock valued at $125,000 after buying an additional 4,700 shares in the last quarter. 38.13% of the stock is owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s work centers on investigational treatments intended to address conditions with significant unmet medical needs.

Protara’s lead product candidate is TARA-002, an investigational cell-based therapy derived from OK-432, a preparation based on a strain of Streptococcus pyogenes. The company is developing TARA-002 for non-muscle-invasive bladder cancer, a form of bladder cancer that has not invaded the bladder muscle, and for lymphatic malformations, rare abnormalities of the lymphatic system.

Protara conducts its research and clinical development activities primarily in the United States.